Stay updated with breaking news from Dermavant Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The announcement by Dermavant followed positive findings from the ADORING trials on tapinarof and an open label extension for children aged 2 - 17.
Approved in 2022 for psoriasis, the manufacturer has submitted an application for approval of tapinarof cream for treating atopic dermatitis in adults and children 2 years of age and older.
Visiongain has published a new report entitled Dermatological Drugs Market Report 2024-2034: Forecasts by Route of Administration (Topical, Oral,...
These new, positive data from the ADORING Phase 3 development program showed no new safety signals with long-term use as well as a significant reduction in disease burden.
/PRNewswire/ -- The Skin of Color Society (SOCS), the global leader in skin of color dermatology, reports that 2023 was a year of exceptional progress in...